| Project/Area Number |
22790144
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Medical pharmacy
|
|---|
| Research Institution | Tohoku University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2010: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
|
|---|
| Keywords | 薬物動態・代謝学 / トランスポーター / 腎不全 / 尿毒症物質 / トランスレーショナルリサーチ / 慢性腎臓病 / メタボローム解析 / スタチン / 酸化ストレス |
|---|
| Research Abstract |
The reduction of accumulated uremic toxins in patients with chronic kidney disease (CKD)protects against the development of cardiovascular diseases. We have revealed that 1)the overexpression of human kidney specific uremic toxin transporter SLCO4C1 in rat kidney promotes renal excretion of uremic toxins and reduced hypertension, cardiomegaly and inflammation in renal failure, 2)statins up-regulate SLCO4C1 to enhance the uremic toxin clearance in renal failure rats (JASN 2009). After newly started stains on CKD patients, representative uremic toxins, guanidino succinate(GSA)and asymmetric dimethylarginine(ADMA)were significantly decreased.
|
